changing paradigms in the management of differentiated ... · • recurrence rate after 131i one...
TRANSCRIPT
Changing paradigms in the management of
Differentiated Thyroid Cancer
Prof. Hisham Mehanna
Chair of Head and Neck Surgery
Director, Institute of Head & Neck Studies & Education
University of Birmingham
www.inhanse.org
Changing paradigms
• Incidence rates • Diagnosis • Personalisation of therapy
– Extent of surgery – Radioiodine ablation – Radioiodine dose
• Dynamic risk stratification and follow-up – Surveillance strategies – TSH suppression
• Mortality
www.inhanse.org
Changing paradigms
• Incidence rates • Diagnosis • Personalisation of therapy
– Extent of surgery – Radioiodine ablation – Radioiodine dose
• Dynamic risk stratification and follow-up – Surveillance strategies – TSH suppression
• Mortality
www.inhanse.org
Incidence of thyroid cancer UK
Incidence rates doubled in 15 years
www.inhanse.org
Global Incidence rates
IARC
www.inhanse.org
Increase in incidence due to increased detection of small sub-clinical disease
www.inhanse.org
Davies JAMA 2006
www.inhanse.org
Davies JAMA 2006
www.inhanse.org
Increase in incidence due to increased detection of small sub-clinical disease
www.inhanse.org
Personalisation of therapy
www.inhanse.org
Traditional mainstay of treatment
Total/completion thyroidectomy +/-
Central nodal dissection +
Radioiodine ablation +
TSH suppression
www.inhanse.org
Case for Total Thyroidectomy
• Retrospective data of large cohorts over long periods (up to 30 year follow-up)
• Mayo Clinic -14,200 patient year experience
Cancer mortality at 25 years HemiT Total T Very low-risk AGES<4 1% 2% Rest AGES>4 65% 35% Hay, Surgery, 1987
www.inhanse.org
Extent of surgery for low risk DTC
• 20 year cost effectiveness of total vs hemi-thyroidectomy. • Pooled published data and decision analysis (Markov). • Cause-specific mortality same. • BUT recurrence free survival (RFS) higher for total thyroidectomy. • Cost effectiveness:
Hemi Total $ $ 20 year OS 15,155 14,317 20 year RFS 19,916 15,440
Shrime et al, Arch Otol HNS, 2007
www.inhanse.org
Case for Hemi-thyroidectomy
Ito Hospital, 1088 pts, Hemi-T, no RIA • Median 17.6 yr follow-up
• Multivariate analysis - factors predictive of DSS
– Age>45 – Tumour size>4cm – LN metastasis – Extrathyroidal extension
• None of patients without any of these features died
Matsuzi, World J Surg, 2014
www.inhanse.org
BTA Guidelines 2014 lobectomy for low risk PTC
• This is relevant for low-risk PTC and FTC with no aggressive features only
• Low-risk DTC: with ALL these features
– Primary less than 4cm in diameter, unifocal disease – <45 years old – No extra-thyroidal extension – No poor histological features – tall cell, sclerosing, widely-invasive (FTC),
angioinvasion (FTC) – No lymph node mets or distant mets – No familial disease
www.inhanse.org
Role of radioiodine in management of DTC
www.inhanse.org
Case for Radio-iodine
• Retrospective data of large cohorts over long periods (up to 30 year follow-up)
• Recurrence rate after 131I one third after thyroid hormone
therapy alone (P < 0.001)
• Likelihood of cancer death decreased significantly by – surgery more extensive than lobectomy, and – 131I plus thyroid hormone therapy Mazzaferri, ey al Am J Med, 1995
www.inhanse.org
Radioiodine in high risk DTC
• In high risk PTC: recommended Tumour >4 cm even without high risk factors evidence for efficacy mainly in >45 year olds , but BTA and ATA also recommends <45 year old Gross extrathyroidal extension regardless of size Incomplete resection Known distant metastasis
www.inhanse.org
Radioiodine in Papillary Thyroid MicroCarcinoma (PTMC)
RIA did not reduce recurrence in PTMC patients with: multi-focal disease (8% vs 7%) or lymph node metastasis (11% vs 10%)
Hay, Surgery, 2008
Ross, Thyroid, 2009 Sakorafas, Cancer Treat Reviews, 2005
Tumours <1cm and no high risk features: No RIA
www.inhanse.org
Radioiodine in intermediate risk DTC
• In intermediate risk PTC: conflicting evidence
• Selected recommendation only for 1-4 cm tumour confined to
thyroid with a combination of high risk features:
– multiple lymph node metastasis (5), large size of involved nodes (6mm), high ratio of positive to negative nodes (0.7), extracapsular nodal extension
– aggressive histology (tall cell, columnar, insular, solid, poorly differentiated, intrathyroid intravascular invasion)
– widely invasive follicular thyroid cancer – multifocal disease >1 cm size – minimal extra-thyroidal spread
British Thyroid Association, 2014
www.inhanse.org
ION TRIAL
CI: Prof Mallick
• Multicentre randomised phase II/III trial
• Phase III: to determine whether the 5-year disease-free survival rate among patients who do not have routine Radioactive iodine (RAI) ablation is non-inferior to those who do.
www.inhanse.org
Eligibility: T1-T3N0/N1, no minimal extracapsular spread, no distant mets Low dose 1.1 GBq versus high dose 3.7GBq RIA Same efficacy: Low dose 85% vs High 88.9% But lower adverse events: low 21% vs 33% Hospitalisation for min 3 days: low 13% vs high 36.3%
www.inhanse.org
TSH suppression and follow-up
www.inhanse.org
TSH suppression and follow-up
Traditionally, everyone got full TSH suppression and thyroglobulin life-long follow-up
www.inhanse.org
Dynamic Risk Stratification
• Determining follow-up intensity and TSH suppression based on risk of recurrence
• Follow-up in those treated with TT and RIA by: – Stimulated Thyroglobulin, and – US scan
www.inhanse.org
Thyroglobulin measurement
• Stimulated thyroglobulin after rhTSH – Either by rhTSH or withdrawal (TSH>30) – sTg <0.5microg/l 98-99.5% probability disease free – sTg >2 microg/l highly accurate for persistent disease Baudin, JCEM, 2003
• Unstimulated thyroglobulin
– uTg <0.15 98.6% negative predictive value for recurrence
– Cost effective alternative to sTg Malandrino, JCEM, 2011
www.inhanse.org
Dynamic Risk Stratification
Excellent Response Indeterminate Response Incomplete Response
All the following: -Suppressed and stimulated Tg<1mcg/L -Neck USS without evidence of disease -Cross-sectional and/or nuclear medicine imaging negative (if performed)
Any of the following: -Suppressed Tg<1mcg/ml and stimulated Tg ≥1 and <10mcg/L -Neck USS with nonspecific changes or stable sub-cm lymph nodes -Cross-sectional and/or nuclear medicine imaging with nonspecific changes, not completely normal
Any of the following: -Suppressed Tg≥1mcg/L or stimulated Tg≥10mcg/L -Rising Tg values Persistent or newly identified disease on US -Persistent or newly identified disease on cross-sectional and/or nuclear medicine imaging
Low risk Intermediate Risk High Risk No TSH supp (0.5-2) Annual Tg/Tg Ab US 2-3 yrs
Mild TSH supp 0.1-0.5 More frequent
TSH suppression <0.1 Frequent as appropriate
www.inhanse.org
Dynamic Risk Stratification
• Good predictor of recurrence – Excellent response: sTg<1 ng/ml, US clear – Incomplete response, sTg>10ng/ml, rising Tg or US shows
structural changes
Low risk group
Inter risk group
High risk group
Excellent response
2% 2% 14%
Incomplete response
13% 41% 79%
Tuttle, Thyroid, 2010
www.inhanse.org
Papillary Thyroid MicroCarcinoma
• BTA 2007: no completion or radio-iodine
• BTA 2014 guidelines: – no TSH suppression – no follow-up
www.inhanse.org
Incidental vs non-incidental
Incidental PTMC Discharge, annual TSH Non-incidental PTMC low risk follow-up Mehanna et al, JCEM, 2014
StudyIncidental PTMC
Wada N, 2003Dietlein M,2005Lo CY, 2006Roti E,2006Schonberger J, 2007Sakorafas GH, 2007Gülben K, 2008Pazaitou-Panayiotou K, 2008Lin JD,2008Besic N, 2009Pisanu A, 2009Xu YN, 2010Summary (I-squared = 0%, p = 0.999)
Non - incidental PTMCWada N, 2003Roti E,2006Lo CY, 2006Schonberger J, 2007Cappelli C, 2007Pazaitou-Panayiotou K, 2008Lin JD, 2008Besic N, 2009Pisanu A, 2009Abboud B, 2010Sugitani I, 2010Xu YN, 2010Ito Y, 2010Moon HJ,2011Summary (I-squared = 89.6%, p < 0.001)
Recurrenceproportion
1/1550/200/750/520/540/271/810/302/1260/1070/730/544/854
6/2594/19113/1103/1348/1023/10220/2097/1473/760/1221/561/12332/105912/288173/2669
0.0060.0000.0000.0000.0000.0000.0120.0000.0160.0000.0000.0000.000
0.0230.0210.1180.2310.4710.1250.0960.0480.0390.0000.3750.0080.0300.0420.079
lower0.0000.0000.0000.0000.0000.0000.0000.0000.0020.0000.0000.0000.000
0.0080.0060.0640.0500.3700.0270.0590.0190.0080.0000.2490.0000.0210.0220.049
95% CIsupper0.0350.1680.0480.0680.0660.1280.0670.1160.0560.0340.0490.0660.011
0.0500.0530.1940.5380.5720.3240.1440.0960.1110.2650.5150.0440.0420.0720.109
wgts%20.5 0.911.0 5.4 5.8 1.6 5.7 1.9 8.722.210.5 5.8100
10.210.1 7.1 1.3 4.8 2.9 8.8 9.1 8.1 3.4 3.410.110.610.0100
0 0.1 0.2 0.3 0.4 0.5
Recurrence Proportion
www.inhanse.org
Increase in incidence due to increased detection of small sub-clinical disease
www.inhanse.org
Increase due to small subclinical tumours?
www.inhanse.org
Rates of nodules >4cm increasing rapidly too!
Male Female <1cm 4.0% 8.6% >4cm 3.9% 5.7%
Annual Percentage increase in USA
Chen Cancer 2009; Zhu Thyroid 2009
www.inhanse.org
Thyroid cancer incidence increased dramatically in >45 compared to <45 in same period in USA
Chen, Cancer, 2009 females males
www.inhanse.org
Period and birth cohort effect = unlikely to be just detection bias!
male
female Zhu,Thyroid, 2009
www.inhanse.org
Mortality has not changed?
www.inhanse.org
Global thyroid mortality rates
If we were detecting subclinical disease mortality rates would remain the same Thyroid mortality rates are decreasing in most countries May be our management is getting better May be by identifying cancers earlier we are preventing mortality
www.inhanse.org
In UK 10% absolute improvement in survival in a decade
www.inhanse.org
Changing paradigms
• Incidence rates • Diagnosis • Personalisation of therapy
– Extent of surgery – Radioiodine ablation – Radioiodine dose
• Dynamic risk stratification and follow-up – Surveillance strategies – TSH suppression
• Mortality
www.inhanse.org
Clinical trials Anjola Awofisoye Gemma Jones June Jones Alison Edmonds Vicki Smith Lynda Wagstaff Nicky Graham Paul Nankivell
Translational Adrian Fisk Sean James Chris McCabe Davy Rapozo Sally Roberts Max Robsinon Vicki Smith Gosia Wiench Ciaran Woodman
Warwick CTU Janet Dunn Tessa Fulton-Lieuw Jo Grummet Chris McConkey Dharmesh Patel Joy Rahman
Clinical Ijaz Ahmed Andrew Hartle Huw Griffiths Chris Jennings Tim Martin Hisham Mehanna Janet O’Connell Linda Orr Sat Parmar Paul Pracy Paul Sanghera James Good Prav Praveen John Watkinson Kristien Boelaert Anthony Kong
Patients Collaborators
InHANSE team
www.inhanse.org
Clinical trials and effectiveness
Experimental and translational medicine
Quality of life
Institute of Head and Neck Studies and Education